Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
EBITDA margins expand to 31.3%
Subscribe To Our Newsletter & Stay Updated